SMARCA5 and breast carcinoma: For example, miR‐424‐5p/circ‐LARP4 (Zhang et al., 2017), miR‐126/circ‐ANKS1B (Zeng, et al., 2018; Zhang et al., 2013), miR‐192‐5p/circ‐SMARCA5 (Gu et al., 2018; Yu et al., 2018), and miR‐106b/circ‐MYLK (Lee et al., 2018; Zhong et al., 2017) were identified as the promising prognostic biomarkers of gastric cancer, breast cancer, hepatocellular carcinoma, and bladder cancer, respectively.